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Summary
Acute graft-versus-host disease (GVHD) is a leading cause of
non-relapse mortality following allogeneic haematopoietic
cell transplantation. Attempts to improve treatment response
in clinically-established GVHD have not improved overall
survival, often due to the increased risk of infectious compli-
cations. Alternative approaches to decrease GVHD-related
morbidity and mortality have focused on the ability to pre-
dict GVHD prior to clinical manifestation in an effort to
provide an opportunity to abort GVHD development, and to
gain new insights into GVHD pathophysiology. This review
outlines the research efforts to date that have identified clini-
cal and laboratory-based factors that are predictive of acute
GVHD and describes future directions in developing algo-
rithms that will improve the ability to predict the develop-
ment of clinically relevant GVHD.
Keywords: bone marrow transplant, graft-versus-host disease,
bone marrow transplant immunology, biomarkers, predic-
tion.
Allogeneic haematopoietic cell transplantation (HCT) is an
increasingly used curative modality for haematological malig-
nancies and other conditions. In recent years, improvements in
infection prophylaxis and monitoring, immunosuppressive
strategies, DNA-based tissue typing, and supportive care mea-
sures have improved outcomes following this procedure.
Despite these advances, acute graft-versus-host disease
(GVHD) remains a significant barrier to more widespread use
of allo-HCT due to the morbidity and mortality from GVHD
and complications resulting from its prevention and treatment.
Acute GVHD primarily affects the skin, liver and gastro-
intestinal (GI) tract, and typically occurs within 2 months
of allo-HCT (Ferrara et al, 2009), although it may occur
later (Jagasia et al, 2012). GVHD occurs when donor T
cells demonstrate immunological intolerance to genetically
defined proteins on host cells (Fig 1) (Ferrara et al, 2009).
Human leucocyte antigens (HLAs), encoded by the major
histocompatibility complex (MHC), are the most influential
proteins. Class 1 HLA proteins (A, B and C) are expressed in
various densities on almost all nucleated cells, while class 2
molecules (DR, DQ and DP) are primarily expressed on B
cells, dendritic cells and monocytes. The likelihood of GVHD
is directly related to the degree of HLA disparity between
patients and donors, but moderate to severe acute GVHD
occurs in roughly 40% of patients receiving HLA-identical
grafts (Jagasia et al, 2012). The only proven front-line therapy
for GVHD is systemic corticosteroid therapy and, despite mul-
tiple clinical trials, no agent has been found that improves
overall survival for patients who fail steroid treatment. This
lack of progress has been due to lack of efficacy, or in the case
of increased GVHD response to treatment, an offset of
increased infectious complications as a result of intensified
immunosuppression (Deeg, 2007).
Due to the incidence of GVHD in the setting of
HLA-matched allo-HCT and lack of advances in GVHD
therapy, many groups have tried to find additional risk
factors that contribute to the subsequent development of
acute GVHD following allo-HCT. These efforts have identi-
fied clinical factors of the patient and donor, as well as
pre-transplant conditioning and GVHD prophylaxis strategies
that are associated with more frequent GVHD. From a labo-
ratory perspective, investigators have identified non-HLA
genetic factors in donors and recipients that correlate with
increased risk for GVHD as well as plasma protein patterns
in the early post-HCT course that predict subsequent GVHD.
Unfortunately, the published efforts have sometimes resulted
in contradictory findings. In this review, we focus on studies
of large registry cohorts that included multivariate analyses
whenever possible and, when not available, studies for which
large numbers of consecutive patients were enrolled. When
only smaller studies were available, we highlight risk factors
which were identified in more than one study. Finally, poten-
tially important risk factors are also identified, even if the
findings are not yet conclusive.
Patient and donor characteristics
Several patient characteristics have been identified that
increase the risk for development of acute GVHD (Table I).
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The risk for acute GVHD rises with increasing patient age,
(Urbano-Ispizua et al, 2002; Lee et al, 2007; Hahn et al,
2008). This effect is due to uncertain mechanisms, but
thymic involution that naturally occurs with age leading to
loss of negative selection of host-reactive T-cell clones has
been proposed as one mechanism (Storb & Thomas, 1985).
Animal HCT models suggest that antigen-presenting cells
of older recipients have increased allostimulatory activity
(Ordemann et al, 2002). In a recently published study of
over 5 500 patients, neither patient or donor age was found
to contribute to GVHD risk on multivariate analysis,
although both were significantly associated with transplant-
related mortality (Jagasia et al, 2012).
The underlying diagnosis for which a patient is receiving
allo-HCT has also been identified as a risk factor; receiving
allo-HCT for chronic myeloid leukaemia (CML) was found
to convey increased risk for GVHD when compared to other
diseases on multivariate analysis in large studies (Remberger
et al, 2002; Hahn et al, 2008; Jagasia et al, 2012). CML is
associated with increased serum concentrations of tumour
necrosis factor a (TNF-a), which may predispose patients to
the development of GVHD (Hahn et al, 2008).
Related donors are more likely to share minor histocom-
patibility antigens, and therefore should experience less
alloreactivity. Thus, it is not surprising that HCT from an
unrelated donor has been shown to increase the risk for
acute GVHD (Stern et al, 2006; Arora et al, 2009; Flowers
et al, 2011). Especially convincing, Flowers et al (2011)
reported risk factors for GVHD in 2941 patients receiving
allogeneic HCT from related (n = 1554) or unrelated
(n = 1387) donors. On multivariate analysis, the use of
an unrelated donor (Hazard Ratio [HR] = 166), HLA-
mismatched donor (HR = 174), the use of total body
irradiation (TBI) in the conditioning regimen (HR =
149), or a female donor for a male recipient (HR = 114)
were all associated with increased risk for GVHD, while
patient age and the use of mobilized peripheral blood
stem cells did not.
The use of an HLA-mismatched donor is widely accepted
to increase the risk of acute GVHD; four reports on large
patient cohorts confirm that anything less than an 8/8
matched donor (at A, B, C and DRB1 loci) conveys increased
risk for GVHD in the absence of T-cell depletion (Lee et al,
2007; Arora et al, 2009; Flowers et al, 2011; Jagasia et al,
2012). When investigating which HLA-antigens contributed
the greatest risk for acute GVHD, a study of 1933 patients
determined increased risk with mismatches of either a C
antigen or a B allele/antigen when compared to donors
matched at A, B, C and DRB1 loci (Woolfrey et al, 2011).
The effect of DP and DQ loci mismatches on GVHD risk is
unclear. Some studies show no increased GVHD risk for DQ
mismatches in multivariate analysis (Flomenberg et al, 2004;
Lee et al, 2007; Woolfrey et al, 2011). In another study,
HLA-DQ mismatch impacted GVHD risk only if another
HLA mismatch existed (Loiseau et al, 2007). Likewise, con-
flicting results have been seen for DP mismatches (Flomen-
berg et al, 2004; Lee et al, 2007; Shaw et al, 2007). The
impact of HLA-matching in the setting of umbilical cord
blood transplantation on GVHD risk has not been clear-cut.
The risk of GVHD when using 5/6 HLA-matched umbilical
cord blood units is comparable to 6/6 matched, but reports
have varied on whether the use of a 4/6 matched graft
increases risk (MacMillan et al, 2009; Geyer et al, 2011). A
large registry study of 803 children found that HLA-disparity
did not appear to impact on acute GVHD risk, although
increasing disparity (two antigen mismatch vs. one antigen
mismatch vs. no mismatches), especially mismatches at
HLA-C, was associated with increased transplant-related
mortality (Eapen et al, 2011).
ABO antigens are expressed on a wide variety of tissues
and it is common for naturally-occurring isoagglutinins to
develop; thus it has been speculated that ABO antigen
disparity between donor and patient may lead antibody-
mediated host tissue damage causing the release of inflam-
matory cytokines and further immune trafficking. Minor
ABO incompatibility was shown to increase the risk for acute
GVHD [HR = 292] (Ludajic et al, 2009), but this associa-
tion was not confirmed in larger studies (Wang et al, 2010;




















Fig 1. Pathophysiology of acute graft-versus-host disease. During the
first phase (I), recipient conditioning regimen damages patient
tissues and causes release of inflammatory cytokines such as TNF-a,
IL-1 and IL-7, which leads to activation of host antigen-presenting
cells (APCs). In the second phase (II), host APCs activate mature
donor cells through IL-12 and IL-23 to produce T helper cell type 1
(Th1) cytokines, such as IL-2, IL-6 and IFN-c. The synthesis of
inflammatory cytokines is partly inhibited by IL-10. Activated Th1
cells induce increased indoleamine 2,3-dioxygenase (IDO) secretion
from host APCs through IFN-c secretion, thus stimulating immunot-
olerizing Tregs. IFN-c also stimulates mononuclear cells to secrete
inflammatory cytokines, such as IL-1 and TNF-a. (III) Th1 cells pro-
mote proliferation and differentiation of activated cytotoxic T lym-
phocytes (CTLs) and stimulate Natural Killer (NK) cells, which, in
turn, induce apoptosis. Lipopolysaccharide (LPS) and bacterial cell
wall components that have leaked through the damaged intestinal
mucosa stimulate mononuclear cells through interactions with
NOD2 and other innate immunity proteins, thus triggering addi-
tional inflammatory cytokine production causing apoptosis.
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Table I. Recipient, Donor and Graft properties influencing aGVHD risk.
Recipient/Donor
Properties Characteristic Impact* Study population (n) References
Recipient Age NSA Related, Unrelated (5561) Jagasia et al (2012)
>30 years HR = 15 [14–17] Unrelated (3857) Lee et al (2007)
>42 years RR = 17 [16–25] Related (315) Urbano-Ispizua et al
(2002)
>40 years HR = 14 [12–18] Related (1960) Hahn et al (2008)
Indication for
transplant
CML HR = 2 [11–36] Related (493) Remberger et al
(2002)
HR = 14 [12–16] Related (1960) Hahn et al (2008)
OR = 15 [11–20] (unrelated
donor only)
Related, Unrelated (5561) Jagasia et al (2012)
Use of unrelated
donor
Use of unrelated donor 26 [18–37] Related, Unrelated (1481) Stern et al (2006)
RR = 24 [21–28] Related, Unrelated (4566) Arora et al (2009)
HR = 17 [15–18] Related, Unrelated (2941) Flowers et al (2011)
HLA Match Any mismatch (on best
available HLA typing)
HR = 2 [18–22] Related, Unrelated (2941) Flowers et al (2011)
HR = 31 [11–86] (4/6 vs. 5–6/6) Unrelated Cord Blood;
Paediatric (88)
Geyer et al (2011)
NSA (4/6 vs. 5/6 vs. 6/6) Unrelated Cord Blood (265) MacMillan et al
(2009)
Any mismatch at HLA-A, -B,
-C, or DRB1
HR = 15 (1 mismatch); HR = 18
(2 mismatches)
Unrelated (1874) Flomenberg et al
(2004)
RR = 26 [22–32] Related, Unrelated (4566) Arora et al (2009)
OR = 13 [11–15] (unrelated
donor only)
Related, Unrelated (5561) Jagasia et al (2012)
NSA (Any degree of mismatch) Unrelated, Cord Blood (803) Eapen et al (2011)
C antigen mismatch; B allele
or antigen mismatch
↑ aGVHD Unrelated (1933) Woolfrey et al
(2011)
>1 mismatch at HLA-A, -B,
-C, -DRB1 or -DQB1
HR = 25 [14–45] (severe GVHD) Unrelated (334) Loiseau et al (2007)
Any mismatch at HLA-A, -B,
-C, DRB1 or DP
HR = 12 [11–14] (1 mismatch);
HR = 16 [15–18] (2
mismatches)
Unrelated (3857) Lee et al (2007)
DQ mismatch NSA Unrelated (1933) Woolfrey et al (2011)
DQ or DP mismatch NSA [085–126] Unrelated (1874) Flomenberg et al
(2004)
DP mismatch, when adjusted
for other mismatch
HR = 13 [11–15] Unrelated (5929) Shaw et al (2007)
ABO Blood Group Minor ABO mismatch HR = 29 [14–60] Unrelated (154) Ludajic et al (2009)
ABO incompatibility NSA Related, Unrelated (1856) Wang et al (2010)
NSA Related, Unrelated (5561) Jagasia et al (2012)
Gender Disparity Female donor to male
recipient
RR = 13 [102–17] Related, Unrelated (1481) Stern et al (2006)
HR = 11 [104–12] Related, Unrelated (2941) Flowers et al (2011)
Alloimmunized female donor
to male recipient





Stem cell source PBSC or BM use NSA Unrelated (513) Anasetti et al (2011)
NSA Related, Unrelated (2941) Flowers et al (2011)
Use of umbilical cord blood
Matched related cord blood
vs. matched related marrow
RR = 04 [02–07] Related; Cord blood (2165) Rocha et al (2000)
Compared to matched
unrelated marrow
HR = 045 [02–096]
(Matched cord blood) NSA
[04–13] (1–2 Mismatched cord)
Unrelated, Cord Blood;
Paediatric (785)




NSA [06–11] (vs. matched
marrow) HR = 07
[04–099] (vs. mismatched
marrow)
Unrelated, Cord Blood (600) Laughlin et al (2004)
2 vs. 1 cord blood unit RR = 2 [12–34] Unrelated Cord Blood (265) MacMillan et al
(2009)
Use of haplo-identical donor
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Multiple reports have shown that the selection of a
female donor for a male patient increases GVHD risk
[HR 133–191] (Stern et al, 2006; Flowers et al, 2011),
particularly when the female is allo-immunized as a result of
previous pregnancy [HR = 355] (Remberger et al, 2008).
These findings may be explained by minor histocompatibility
Table I. (Continued)
Recipient/Donor





Cho et al (2012)
Compared to matched related,
matched unrelated donors




Stem cell dose High CD34+ cell dose HR = 26 [13–53] Related (315) Urbano-Ispizua et al
(2002)
CD34+ cell dose NSA Unrelated (932) Pulsipher et al
(2009)
Treg Low Treg content in graft ↑ aGVHD Related (32) Rezvani et al (2006)






HR = 03 [01–07] Related (137) Couriel et al (2004b)
OR = 009 [001–06] Related (110) Mlynarczewska et al
(2004)
↓ aGVHD Related, Unrelated (5561) Jagasia et al (2012)
HR = 02 [01–05] Unrelated Cord Blood;
Paediatric (88)
Geyer et al (2011)
Conditioning-
related Toxicity
No oral intake for >9 d OR = 77 [14–407] (severe
GVHD)





(days 3 to 0), or
>894 ml/kg max)
OR = 6–12 Related (101) Liu et al (2010)
TBI use in
conditioning
Use of TBI HR = 14 [12–17] Related (1960) Hahn et al (2008)










OR = 2 [11–37] Related, Unrelated (304) Wermke et al (2010)
Use of Tacrolimus in
GVHD prophylaxis
OR = 06 [05–09] (related donor)
OR = 08 [07–09] (unrelated
donor)
Related, Unrelated (5561) Jagasia et al (2012)





RR = 06 Related (329) Ratanatharathorn et
al (1998)
↓ aGVHD Unrelated (180) Nash et al (2000)
In vivo T-cell depletion
With anti-thymocyte
globulin




RR = 05 [03–09] Unrelated Cord Blood (265) MacMillan et al
(2009)
OR = 03 [02–06] Related, Unrelated (304) Wermke et al (2010)
NSA [07–104] Related, Unrelated (1676) Soiffer et al (2011)
With alemtuzumab HR = 04 [03–06] (vs. T-cell
replete) HR = 04 [03–05]
(vs. ATG)
Related, Unrelated (1676) Soiffer et al (2011)
NSA (vs. ATG) Related, Unrelated (108) Norlin & Remberger
(2011)
*Relative risk (RR), hazard ratio (HR) or odds ratio (OR) provided when reported, otherwise increased or decreased risk is reported. Confidence
intervals, when provided, are in brackets.
aGVHD, acute graft-versus-host disease; TBI, total body irradiation; CML, chronic myeloid leukaemia; ATG, antithymocyte globulin; NSA, no
significant association; RR, relative risk; HR, hazard ratio; OR, odds ratio.
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antigens encoded on the Y chromosome (H-Y antigens)
whose presence in male donors may be recognized by grafts
from female donors and cause alloreactivity (Miklos et al,
2004).
Graft properties
Graft properties have also been identified as risk factors for
the development of acute GVHD (Table I). The selection of
peripheral blood stem cells did not impact the incidence of
GVHD in a phase III, prospective, randomized clinical trial
in unrelated donors (Anasetti et al, 2011), or in a large,
single centre study (Flowers et al, 2011).
When suitably HLA-matched donors are unavailable, HCT
may be performed using grafts from alternative donors
(umbilical cord blood units, haplo-identical related donors),
although these alternative donor sources provide unique clin-
ical challenges (Anasetti et al, 2012). Cord blood transplanta-
tion is associated with delayed cell count recovery and
increased risk of graft failure, which subsequently places
patients at risk for haemorrhage and/or life-threatening infec-
tion. Either in vivo/ex vivo T-cell depletion or aggressive
immunosuppressive GVHD prophylaxis strategies are used to
minimize the risk associated with the HLA-disparity inherent
to haplo-identical transplantation. These strategies predispose
recipients to delayed immune reconstitution, thus increasing
risk of infection and relapse of underlying malignancy. Large
studies (n = 2165 and 785, respectively) have demonstrated
decreased risk of GVHD when using related donor
HLA-matched cord blood compared to HLA-matched
marrow grafts from either related or unrelated donors
(Rocha et al, 2000; Eapen et al, 2007). Likewise, unrelated
donor cord blood units that are 4–6/6 HLA-matched provide
comparable GVHD risk to matched unrelated donor grafts
(Laughlin et al, 2004; Eapen et al, 2007). These findings
highlight that when HLA-matching is similar, cord blood
transplants confer less GVHD risk compared to bone marrow
or peripheral blood as a stem source. Furthermore, the risk
of GVHD is comparable for HLA-mismatched cord blood
units compared to matched bone marrow or peripheral
blood transplants. The predominance of na€ıve T-cells in cord
blood grafts may explain these findings. However, when two
unrelated umbilical cord blood units are transplanted simul-
taneously to overcome risk of graft rejection, the risk of
GVHD is elevated compared to single cord unit grafts
(MacMillan et al, 2009).
Provided that intensive GVHD prophylaxis is given,
haplo-identical marrow transplantation strategies result in
comparable risk of GVHD with standard graft transplan-
tation (Burroughs et al, 2008; Cho et al, 2012). However,
no prospective studies have been reported that directly
compare GVHD risk between umbilical cord blood and
haplo-identical transplantation.
The immunophenotypic makeup of the graft may also
influence GVHD risk. High CD34+ stem cell dose was
reported to increase the risk of GVHD in related donors
(Urbano-Ispizua et al, 2002), although a larger study found
no association in unrelated donors (Pulsipher et al, 2009).
Regulatory T-cells (Treg) are a subset of T lymphocytes that
suppress immune activation, thus reducing alloreactivity.
High graft Treg content has been shown to decrease the risk
of acute GVHD (Rezvani et al, 2006; Wolf et al, 2007).
Initial trials of Treg enrichment/expansion to prevent GVHD
have been promising and further research efforts are
on-going (Hippen et al, 2011).
Conditioning/Post-HCT management
Research efforts have tried to identify transplant conditioning
and GVHD prophylaxis strategies that can decrease GVHD
risk (Table I). GI tract damage plays an important role in
GVHD pathophysiology (Hill & Ferrara, 2000). Condition-
ing-associated damage of the GI mucosa allows increased
translocation of inflammatory stimuli, such as lipopolysac-
charide, an endotoxin present in the normal bacterial flora of
the GI tract, which promotes the release of inflammatory
cytokines and further damage to the GI tract (Fig 1). This
may partly explain repeated findings with different graft
sources of decreased GVHD incidence associated with the
use of reduced-intensity conditioning regimens that result in
lowered conditioning-related GI damage (Couriel et al,
2004a; Mlynarczewska et al, 2004; Geyer et al, 2011; Jagasia
et al, 2012). The increased risk for GVHD in patients experi-
encing more GI damage has been supported by clinical
observations of higher incidences of GVHD in patients who
experienced prolonged periods without oral intake [HR 77,
P = 002] (Mattsson et al, 2006), or severe diarrhoea in the
early post-transplant period [39% vs. 6%, P < 0001]
(Liu et al, 2010). Likewise, the inclusion of TBI in the condi-
tioning regimen has reproducibly increased the risk of acute
GVHD (Hahn et al, 2008; Flowers et al, 2011; Jagasia et al,
2012), which suggests that damage caused by radiation may
be immunologically-recognized differently from that of
myeloablative chemotherapy.
Several studies have investigated GVHD prophylaxis strat-
egies and development of acute GVHD. Single-agent GVHD
prophylaxis with either cyclosporine or methotrexate was
shown to increase risk of GVHD over multi-agent prophy-
laxis (Remberger et al, 2002; Wermke et al, 2010). The use
of tacrolimus in the prophylaxis regimen was shown to
decrease the risk for acute GVHD (Jagasia et al, 2012),
particularly when used in combination with methotrexate
(Ratanatharathorn et al, 1998; Nash et al, 2000). Ratanatha-
rathorn et al (1998) and Nash et al (2000) confirmed the
superior efficacy of GVHD prophylaxis using tacrolimus and
methotrexate when compared to cyclosporine and metho-
trexate in phase III randomized clinical trials for related and
unrelated donor HCT, respectively.
In vivo T-cell depletion reduces GVHD risk in a number
of transplant settings (Remberger et al, 2008; MacMillan
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et al, 2009; Wermke et al, 2010), which is unsurprising given
the central role T lymphocytes play in GVHD physiology
(Fig 1). This strategy is not universally implemented how-
ever, due to increased risk for complications, such as
Epstein-Barr virus post-transplant lymphoproliferative disor-
der (PTLD), infection and relapse (Soiffer et al, 2011). The
efficacy of the anti-CD52 antibody, alemtuzumab, which
targets lymphocytes, monocytes and dendritic cells, in
reducing GVHD beyond that afforded by anti-thymocyte
globulin is not clear. GVHD rates were comparable when
receiving alemtuzumab or anti-thymocyte globulin in one
study (Norlin & Remberger, 2011). By contrast, a large
registry-based study found a significant reduction in GVHD
incidence with alemtuzumab use when compared to trans-
plantation with T-replete grafts or use of anti-thymocyte
globulin, and no decreased GVHD risk after the use of
anti-thymocyte globulin when compared to T-replete graft
transplantation (Soiffer et al, 2011).
Genetic factors
There have been many reports identifying genetic predisposi-
tion for acute GVHD in both recipients and donors
(Table II). Most of these studies have focused on fully
HLA-matched donor/patient pairs to remove the known
acute GVHD risk associated with HLA-mismatched HCT. As
one might expect, a majority of the identified genetic poly-
morphisms are within genes encoding for innate immunity
or inflammatory/immunoregulatory proteins.
Innate immunity
One of the most frequently studied genetic predictors
of acute GVHD is nucleotide-binding oligomerization
domain containing protein 2 (NOD2), which encodes an
intracellular receptor (NOD2) that binds bacterial cell wall
products resulting in upregulated nuclear factor kappa B
(NFjB) activation (Fig 1). Several NOD2 variants, which
can be identified by the presence of single nucleotide
polymorphisms (SNPs), result in a decreased capacity to
release inflammatory cytokines in response to bacterial
wall products. The presence of donor and/or recipient
NOD2 variants (SNPs 8, 12 and 13) were originally iden-
tified as risk factors for GVHD (Holler et al, 2004). Some
groups have reported that the presence of NOD2 variants
in either donors, recipients, or both, confers increased
risk of GVHD (Elmaagacli et al, 2006; Holler et al, 2008),
while other groups have not been able to replicate these
findings (Sairafi et al, 2008; Gruhn et al, 2009; Nguyen
et al, 2010; Wermke et al, 2010). The difference may be
due to variability in patient populations or differences in
HCT strategies, such as the use of in vivo T-cell depletion,
gut decontamination, or less toxic conditioning regimens
decreasing the extent of GI damage (van der Velden et al,
2011).
Inflammatory/Immunoregulatory genes
The role of pro-inflammatory (e.g. interferon-gamma [IFN-c],
TNF, interleukin-6 [ILIL6], etc.) and anti-inflammatory pro-
teins is well established in GVHD pathophysiology (Fig 1).
Several groups have investigated how genetic polymorphisms
that modulate activity and/or expression of these proteins
influence GVHD risk.
Different polymorphisms of interleukin-10 (IL-10, IL10), a
protein that inhibits the synthesis of inflammatory cytokines
and polarizes lymphocytes to a T-helper cell type 2 (Th2)
response, have been investigated as genetic risk factors for
acute GVHD. The number of dinucleotide repeats in the
upstream regulatory region of the IL10 gene affect IL-10 pro-
duction, with patients possessing larger number of dinucleo-
tide repeats (denoted as alleles 12–15) producing less IL-10.
Recipients possessing low IL-10 producing genotypes have
been found to have increased GVHD incidence following
HCT (Cavet et al, 2001; Middleton et al, 2002; Nordlander
et al, 2002). The influence of IL-10 promoter polymorphisms
on GVHD risk, primarily -1082(A/G), -819(C/T) and -582
(A/C), has also been investigated. Three common haplotypes
represent high (GCC), intermediate (ATA) and low (ACC)
IL-10 production (Suarez et al, 2003). As one might expect,
the presence of the high-producing (GCC) haplotype in HCT
recipients correlated with decreased risk for aGVHD (Kara-
bon et al, 2005; Goussetis et al, 2011). Contrary results were
reported in one large study, however, that found the pres-
ence of recipient or absence of donor GCC haplotype
increased risk for GVHD (Socie et al, 2001). Another study
found no association between -1082, -819, -582 haplotype
and GVHD risk (Mullighan et al, 2004).
TNF-a is an inflammatory cytokine that is involved in
GVHD pathology (Fig 1). TNFd is a dinucleotide repeat
sequence that is positioned downstream of the TNF gene for
which different alleles have been found to alter TNF-a pro-
duction. The TNF d3/d3 and d4/d4 genotypes are associated
with increased TNF-a production compared to other poly-
morphisms. Patients who carry the d3/d3 genotype showed
increased rates of GVHD in some (Middleton et al, 1998;
Cavet et al, 2001), but not other studies. An increased
GVHD risk was found in patients with the d4/d4 – but not
d3/d3 – genotype (Nordlander et al, 2002; Goyal et al, 2010).
The two studies that found a positive correlation between
TNF d3/d3 and GVHD did not report findings for the d4/d4
genotypes. Despite multiple attempts, no association has
been found between the polymorphism in the TNF promoter
region at position -308, also associated with increased TNF-a
production, and GVHD risk (Middleton et al, 1998; Socie
et al, 2001; Nordlander et al, 2002; Rocha et al, 2002; Lin
et al, 2003).
Polymorphisms of genes related to interleukin-1 (IL-1),
IL1A, IL1B and IL1RN, have been examined for their role in
acute GVHD due to the role of IL-1 in promoting GVHD
pathophysiology (Fig 1). Polymorphisms of IL1A and IL1B,
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Table II. Genetic polymorphisms influencing aGVHD risk.
Gene Polymorphism Impact* Study population (n) Reference
IFNG IFNG Intron genotype NSA Related (100) Socie et al (2001)
Recipient IFNG Intron 3/3 OR = 39 [12–124] Related (80) Cavet et al (2001)
↑ aGVHD Related(88) Middleton et al (2002)
Recipient IFNG Intron 2/2 OR = 02 [005–099] Related (110) Mlynarczewska et al (2004)
IL1A 889(C/T) NSA Unrelated (90) MacMillan et al (2003)
NSA Unrelated (426) Mehta et al (2007)
IL1RN IL1RN*2 NSA Related (570) Lin et al (2003)
NSA Unrelated (90) MacMillan et al (2003)
Absence of donor IL1RN*2 OR = 62 Related (99) Cullup et al (2001)
HR = 21 [11–39] Related (107) Rocha et al (2002)
IL1B 511(C/T) NSA Related (570) Lin et al (2003)
NSA Unrelated (90) MacMillan et al (2003)
+3953(C/T) NSA Related (77) Bertinetto et al (2006)
+3954(C/T) NSA Related (570) Lin et al (2003)
IL6 174(C/G) NSA Related (570) Lin et al (2003)
Recipient 174(G/G) HR = 41 Related (108) Middleton et al (2003)
OR = 22 [11–45] Related, Unrelated (166) Ambruzova et al (2009)
Donor 174(G/*) HR = 43 [15–121] Related (160) Mullighan et al (2004)
Donor -174(G/G) OR = 39 [11–140] Related (93) Karabon et al (2005)
IL10 1064: Increased dinucleotide
repeats (Alleles 12–15)
Recipient with Alleles 12–15 OR = 46 [12–178] Related (80) Cavet et al (2001)
↑ aGVHD Related (88) Middleton et al (2002)
Recipient homozygous for
allele 13
↑ aGVHD Related, Unrelated (196) Nordlander et al (2002)
1082(A/G), 819(C/T),
592(A/C) Haplotype
NSA Related (160) Mullighan et al (2004)
Recipient (GCC/GCC) OR = 009 [001–096] Related (93) Karabon et al (2005)
HR = 02 [006–07]
(severe GVHD)
Related; Paediatric (57) Goussetis et al (2011)
RR = 79 [29–215] Related (100) Socie et al (2001)
Donor (GCC/GCC) RR = 03 [01–08] Related (100) Socie et al (2001)
Absence of both donor and
recipient (GCC)
OR = 29 [11–77] Related (77) Bertinetto et al (2006)
IL23R 1142A>G
Donor 1142(G/*) RR = 05 [03–097] Related, Unrelated (407) Elmaagacli et al (2008)
↓ aGVHD Related, Unrelated,
Haplo-identical;
Paediatric (231)
Gruhn et al (2009)
OR = 04 [02–095] Related, Unrelated (304) Wermke et al (2010)
variant SNPs NSA [05–23] Unrelated (390) Nguyen et al (2010)




Gruhn et al (2009)
NSA [06–23] Unrelated (390) Nguyen et al (2010)
NSA [04–15] Related, Unrelated (304) Wermke et al (2010)
Donor only SNPs RR = 0003 [0002–0007]
(severe GVHD)
Related, Unrelated (403) Elmaagacli et al (2006)
Simultaneous SNPs in donor
and recipient:
RR = 43 [21–93]
(severe GVHD)
Related, Unrelated (403) Elmaagacli et al (2006)
1+ variant in either donor or
recipient
↑ aGVHD Related, Unrelated (700) Holler et al (2008)
Donor SNP13 ↑ aGVHD (unrelated only) Related, Unrelated (700) Holler et al (2008)
TNF TNFd3 NSA Related (100) Socie et al (2001)
NSA Related, Unrelated (196) Nordlander et al (2002)
NSA Unrelated, Paediatric (180) Goyal et al (2010)
Recipient TNF d3/d3 ↑ aGVHD Related (49) Middleton et al (1998)
OR = 33 [11–102] Related (80) Cavet et al (2001)
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which encode for the IL-1a (IL1A) and IL-1b (IL1B) mem-
bers of the IL-1 cytokine family, have not been associated
with acute GVHD risk (Lin et al, 2003; MacMillan et al,
2003; Bertinetto et al, 2006; Mehta et al, 2007). IL1RN
encodes for IL-1Ra (IL1RN), an IL-1 antagonist that compet-
itively binds the IL-1 receptor. Allele 2 of IL1RN (IL1RN*2)
is associated with increased plasma concentrations of IL-1Ra
(Hurme & Santtila, 1998), and was predicted to decrease
GVHD incidence. The absence of donor IL1RN*2 (Cullup
et al, 2001; Rocha et al, 2002), or presence of patient
IL1RN*2 (Bertinetto et al, 2006) increased rates of aGVHD
in some studies, although others reported no significant asso-
ciation (Lin et al, 2003; MacMillan et al, 2003).
Several studies have investigated interferon-gamma (IFNG)
polymorphisms and their influence on GVHD. IFNG*2 is
associated with a thymine at position +874 and 12 dinucleo-
tide repeats, while alleles 3, 4, and 5 all have an adenine at
+874 but possess different numbers of dinucleotide repeats
(Pravica et al, 2000). IFNG*2 is associated with higher pro-
duction of IFN-c than other alleles. IFNG*3 in the recipient
may increase the likelihood of aGVHD (Cavet et al, 2001;
Middleton et al, 2002), while IFNG*2 may be protective
(Mlynarczewska et al, 2004), although one large study did
not find significant correlation between either donor or reci-
pient IFNG +874(T/A) polymorphisms and GVHD risk
(Socie et al, 2001). The association of high-IFN-c producing
phenotype with lower GVHD risk suggests that IFN-c pro-
duction in the setting of allo-HCT may have a more potent
immunotolerizing effect, perhaps through induction of
indoleamine 2,3-dioxygenase (IDO) secretion by host anti-
gen-presenting cells, rather than a proinflammatory effect on
mononuclear cells as expected when IFN-c is present in high
concentrations (Fig 1).
Possession of the IL6 polymorphism containing the G
allele at IL6 -174 is associated with increased serum levels of
the proinflammatory cytokine IL6 in normal individuals.
Researchers have found that recipients (Middleton et al,
2003; Ambruzova et al, 2009) or donors (Mullighan et al,
2004; Karabon et al, 2005) homozygous for IL6 -174(G/G)
correlated with higher rates of GVHD compared to non-
homozygous pairs, although no association was found in a
large, independent study (Lin et al, 2003).
The interleukin-23 receptor (IL-23R, IL23R) is present on
many immune effector cells which, when bound by IL-23
activates inflammatory signalling through the JAK/STAT
pathway leading to T-cell activation and proliferation. IL-23
has been implicated in many autoimmune conditions (Duval-
let et al, 2011). An IL23R SNP at position 1142 where an
adenine is substituted with a guanine (1142G>A) has recently
been found to lead to selective loss of function on T cells,
rendering them insensitive to IL-23 (Sarin et al, 2011). This
polymorphism in the donor correlated with a lower incidence
of acute GVHD (Elmaagacli et al, 2008; Gruhn et al, 2009;
Wermke et al, 2010), however one study found no association
of this SNP with GVHD risk (Nguyen et al, 2010).
Allelic variation of the vitamin D receptor (VDR) has also
been investigated for its impact on the development of acute
GVHD. Vitamin D has been shown to polarize T-cell popu-
lations towards Th2 cytokine production, blunt T-cell prolif-
eration in response to dendritic cell activation, and to
increase IDO expression leading to improved immune toler-
ance through Treg stimulation (Fig 1) (Rosenblatt et al,
Table II. (Continued)
Gene Polymorphism Impact* Study population (n) Reference
TNFd4
Recipient TNF d4/d4 HR = 23 (severe GVHD) Unrelated, Paediatric (180) Goyal et al (2010)
Recipient TNFd4 43 [13–146] (related only) Related, Unrelated (196) Nordlander et al (2002)
308(A/G) NSA Related (100) Socie et al (2001)
NSA Related (107) Rocha et al (2002)
NSA Related, Unrelated (196) Nordlander et al (2002)
NSA Related (570) Lin et al (2003)
NSA Related (49) Middleton et al (1998)
VDR ApaI(A/a)
Recipient ApaI(a/*) ↑ aGVHD Related (88) Middleton et al (2002)
Donor ApaI(A/A) OR = 72 [16–321] Related, Unrelated, Haplo-
identical (123)
Bogunia-Kubik et al (2008)
Taql(T/t)
Recipient TaqI(T/*) HR = 26 [12–56] (severe
GVHD)
Related (107) Rocha et al (2009)
FokI(F/f)
Donor FokI(F/F) OR = 45 [12–165] Related, Unrelated, Haplo-
identical (123)
Bogunia-Kubik et al (2008)
*Relative risk (RR), hazard ratio (HR) or odds ratio (OR) provided when reported, otherwise increased or decreased risk is reported. Confidence
intervals, when provided, are in brackets.
aGVHD, acute graft-versus-host disease; NSA, no significant association; SNP, single nucleotide polymorphism; RR, relative risk; HR, hazard
ratio; OR, odds ratio.
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2010). Genetic polymorphisms have been identified that
affect vitamin D receptor transcription and/or activity,
including alleles of the ApaI and TaqI sites, located in intron
8 and 9, respectively, which influence vitamin D receptor
activity. The ‘A’ allele of ApaI (as compared to the ‘a’ allele)
and the ‘t’ allele of TaqI (compared to the ‘T’ allele) are
associated with higher vitamin D activity as evidenced by
higher levels of vitamin D receptor responsive gene products
such as osteocalcin (Uitterlinden et al, 2004). Transplant
recipients with at least one ‘a’ or ‘T’ allele, ApaI(a/*), or
TaqI(T/*), which both correspond to lower vitamin D recep-
tor activity, have been shown be at increased risk for aGVHD
(Middleton et al, 2002; Rocha et al, 2009). Donor ApaI(A/A)
or FokI(F/F) has also been reported to increase risk for
GVHD on multivariate analysis (Bogunia-Kubik et al, 2008).
The ‘F’ allele of FokI produces a shorter vitamin D receptor
protein than the ‘f’ allele, (424 vs. 427 amino acids in
length), and the shorter protein encoded by the ‘F’ allele has
been shown to be the more active vitamin D receptor vari-
ant. It is not clearly understood why increased acute GVHD
risk might be associated with decreased vitamin D receptor
activity polymorphisms in the recipient and conversely, with
higher activity polymorphisms in the donor, but this finding
may possibly be explained by differences in vitamin D effect
on recipient tissues and donor alloreactive T cells.
In summary, numerous reports have identified genetic
polymorphisms that correlate with increased risk for acute
GVHD in large patient cohorts, but these findings are often
contradictory or could not be replicated. One explanation for
the inconsistent findings may be that a biased approach was
commonly used in that small numbers of selected genes were
evaluated. It is likely that multiple genetic factors that impact
risk of GVHD are present in any given patient. The distribu-
tion of these factors may also vary in different patient popu-
lations. Large-scale, whole genome approaches are needed to
better understand the interplay across different genetic fac-
tors that impact GVHD risk. Currently, genetic risk factors
are not routinely evaluated prior to transplantation, although
advances in technology may make genotyping readily avail-
able and cost effective. Once available, however, there may
be barriers to utilizing high-risk polymorphisms to select
donors due to limited availability of fully HLA-matched
donors, which is the most important genetic factor to use in
donor selection. More likely, genetic factors will be used to
risk stratify patients and guide GVHD prevention strategies.
Plasma proteins
Several groups have tried to identify plasma protein profiles
in the pre- and early post-HCT time period that are predic-
tive for subsequent development of acute GVHD (Table III).
While pre-HCT characteristics and genetic polymorphisms
may help to identify which patients have an increased risk
for acute GVHD, they do not identify individual patients in
Table III. Post-HCT protein concentrations influencing aGVHD risk.
Plasma
Protein Characteristic Impact Study population (n) References
CD8 CD8 >129 u/ml at day 15 ↑ aGVHD Related, Unrelated (61) August et al (2011)
CD40L Plasma concentrations post-transplant NSA Related, Unrelated (61) Ambruzova et al (2009)
IL2R IL2R >22 ng/ml at day 15 ↑ aGVHD Related, Unrelated (61) August et al (2011)
IL6 Increased IL6 levels from day +1 until
day +21
↑ aGVHD Related(101) Liu et al (2010)
Plasma IL6 concentrations during
conditioning
NSA Related, Unrelated (112) Remberger et al (1995)
IL7 Increased day 7 and/or day 14 IL7 ↑ aGVHD Related (31) Dean et al (2008)
Day 14 IL7 >119 pg/ml ↑ aGVHD Related, Unrelated; Full intensity (40) Thiant et al (2010)
Day 30 IL7 >59 pg/ml ↑ aGVHD Related, Unrelated; Reduced intensity (45) Thiant et al (2011)
sBAFF sBaff >43 pg/ml prior to conditioning
and at days 0, 7 and 14
↓ aGVHD Related, Unrelated; Full intensity (45) Cho et al (2010)
TNFa Higher TNFa levels during conditioning ↑ aGVHD Related, Unrelated (112) Remberger et al (1995)
Increased TNFa transcription ↑ aGVHD; Related, Unrelated (23) Ritchie et al (2005)
Day 7/Baseline TNFR1 ratio >25 HR = 24 Related, Unrelated; Full intensity (438) Choi et al (2008)
↑ aGVHD
severity
Related, Unrelated; Full intensity;
Paediatric (82)
Kitko et al (2008)
High Day 7/Baseline TNFR1 ratio ↑ aGVHD Related, Unrelated; Reduced intensity
(106)
Willems et al (2010)
TNFR1 >1040 pg/ml at day 15 ↑ aGVHD Related, Unrelated (61) August et al (2011)
Increased TNFa levels from day +1
until day +21
↑ aGVHD Related (101) Liu et al (2010)
*Relative risk (RR), hazard ratio (HR) or odds ratio (OR) provided when reported, otherwise increased or decreased risk is reported. Confidence
intervals, when provided, are in brackets.
aGVHD, acute graft-versus-host disease; NSA, No significant association; RR, relative risk; HR, hazard ratio; OR, odds ratio.
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whom the alloreaction that will culminate in GVHD is
underway. Changes in plasma proteins associated with
inflammation/alloreactivity or markers of target organ
damage (GVHD biomarkers) in the early post-transplant
period may offer a look into the earliest stages of GVHD
pathophysiology prior to clinical manifestations, thus provid-
ing clinicians with a potential window to intervene and abort
the GVHD process.
The most frequently reported protein elevated prior to
GVHD onset is TNFa, an inflammatory cytokine, with
reports showing increased concentrations during HCT condi-
tioning as predictive for post-HCT GVHD (Remberger et al,
1995), and several reports showing elevated Day 7 post-
HCT/pre-HCT ratios are predictive for acute GVHD (Choi
et al, 2008; Kitko et al, 2008; Willems et al, 2010). Other
groups have shown increased TNF transcription (Ritchie
et al, 2005), increased concentrations at day 15 post-HCT
(August et al, 2011), and increased concentrations in the first
3 weeks post-HCT are predictive of later GVHD (Liu et al,
2010). These findings have led to clinical trials of TNFa
blockade as either GVHD prophylaxis (Choi et al, 2012) or
treatment in combination with steroid therapy (Couriel et al,
2004b; Levine et al, 2008); these initial studies identified a
potential benefit from TNFa blockade. A multicentre trial
investigating the efficacy of adding an additional treatment
to steroids at the onset of grade 2–4 GVHD (mycophenolate
mofetil, etanercept, pentostatin, denilileukin deftitox) did not
find additive benefit of etanercept to steroids at GVHD
onset, however (Alousi et al, 2009). The findings of the mul-
ticentre study should be interpreted with caution due to the
allowance of patients who developed grade 2–4 GVHD while
on mycophenolate mofetil GVHD prophylaxis to participate
on the study and be randomized to non-mycophenolate
treatment arms. Patients who had already failed mycopheno-
late therapy and may be less responsive to treatment were
assigned to the non-mycophenolate treatment arms.
Interleukin 7 (IL-7, IL7) is a growth factor that is impor-
tant for homeostatic proliferation of lymphocytes (Boyman
et al, 2012), particularly in periods of severe lymphopenia,
such as shortly after HCT, which results in expansion of
mature donor lymphocyte populations. Increased IL-7 con-
centrations at days 7 and 14 post-HCT correlated with later
acute GVHD in matched related donor HCT (Dean et al,
2008). The significance of day 14 IL-7 concentrations was
validated in patients receiving HCT following myeloablative
conditioning (Thiant et al, 2010). Likewise, following
reduced intensity conditioning, day 30 IL-7 concentrations
correlated with the later onset of GVHD as is often seen in
this setting (Thiant et al, 2011).
Other plasma protein/cytokines identified in reports
include IL-6 (IL6), with increased concentrations during the
first 3 weeks post-HCT predicting later GVHD (Liu et al,
2010), although concentrations during conditioning had no
apparent association with subsequent GVHD development
(Remberger et al, 1995). Elevated concentrations of 3
proteins found on the surface of cytotoxic T cells, CD40L,
CD8 and IL-2R, at day 15 post-HCT have all been associated
with subsequent development of acute GVHD (August et al,
2011), but these findings have not been repeated. In addi-
tion, increased soluble B-cell activating factor (sBAFF) con-
centrations in the early post-HCT period have been
associated with a decreased risk of developing acute GVHD
(Cho et al, 2010). The protective effect of sBAFF may be
explained, in part, by BAFF-directed expansion of immuno-
tolerant Tregs, which was described in an animal skin
allograft model (Walters et al, 2009).
Diagnostic and prognostic GVHD Biomarkers
Several biomarkers diagnostic for acute GVHD have recently
been identified by the University of Michigan Blood and
Marrow Transplant group. The initial report identified a
panel of 4 biomarkers, IL2Ra, TNFR1, hepatocyte growth
factor (HGF) and IL-8 (IL8), that were elevated at the onset
of GVHD when compared to plasma samples at similar time
points from patients who never developed GVHD (Paczesny
et al, 2009). This study did not compare plasma concentra-
tions of patients at GVHD onset with those of patients who
had similar symptoms (rash or diarrhoea) that were proven
to be from other causes, however, so investigators sought
organ-specific biomarkers that could differentiate GVHD
rash or diarrhoea from other causes of similar symptoms.
Elafin, a protease found in the skin with antimicrobial prop-
erties (Verrier et al, 2012), was discovered and validated as a
plasma biomarker of skin GVHD through a large-scale, unbi-
ased proteomic approach (Paczesny et al, 2010a). Elevated
plasma concentrations of elafin help discriminate GVHD rash
from rashes of other causes (e.g. medication effect). Likewise,
REG3a, an antibacterial protein found in Paneth cells of the
small intestine (Cash et al, 2006), was subsequently identified
and validated as a lower GI GVHD biomarker using the
same proteomic strategy (Ferrara et al, 2011). Plasma REG3a
concentrations help discriminate GVHD from other aetiolo-
gies of post-HCT diarrhoea, such as infection and condition-
ing-related toxicity. REG3a was the first diagnostic GVHD
biomarker that predicted treatment response; higher concen-
trations at the onset of lower GI GVHD correlated with
steroid-refractory disease. Interestingly, both target organ-
specific biomarkers are innate immunity proteins.
Elevated concentrations of the aforementioned GVHD
biomarkers at GVHD onset also correlate with increased
non-relapse mortality (NRM). In the REG3a study (Ferrara
et al, 2011), 3 high-risk parameters were identified at the
onset of GVHD diarrhoea that each independently predicted
1-year NRM: onset clinical severity (>1 l of stool per day
and/or bloody stool [stages 2–4] vs. <1 l of stool per day
[stage 1]), severity of histological findings on diagnostic
biopsy (complete denudation [stage 4] vs. less severe damage
[stages 1–3]), and high REG3a concentrations (>151 ng/ml
vs. lower concentrations). Patients with any 2 risk factors
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present at onset had significantly higher NRM (66%) than
those with no or any 1 onset risk factor (25% and 34%,
respectively, P < 0001), and patients with all 3 risk factors
present had significantly higher 1-year NRM than those with
any 2 risk factors (86% vs. 66%, P < 0001). If this novel
scoring system at the onset of lower GI GVHD is confirmed
in additional patients, it may permit better risk stratification
of patients with lower GI GVHD, thus identifying patients in
whom standard GVHD therapy may be insufficient.
A similar proteomics approach has been taken to identify
protein fragments in the urine of post-HCT patients that
identified acute GVHD at onset (Weissinger et al, 2007). A
31-peptide pattern appeared to correlate with acute GVHD,
but the identity of the components remains largely unre-
ported. The two peptides that were identified were collagen
1-a fragments, and it is unclear how these may relate to
GVHD-specific pathophysiology.
Biomarker panels
The association of elevated TNFR1 ratios with subsequent
development of GVHD prompted researchers at the Univer-
sity of Michigan to measure diagnostic biomarkers (IL2Ra,
TNFR1, and elafin) at day 0, day 7 and day 14 following
unrelated donor allogeneic HCT in patients who had not yet
developed acute GVHD with the intent of finding biomarker
patterns that predicted GVHD. Logistic regression was used
to assign individual weights to each biomarker and deter-
mine which biomarkers contributed to the most sensitive
and specific predictive algorithm. The peak concentrations of
IL-2Ra, TNFR1 and elafin were used to categorize patients at
high or low risk for acute GVHD. Day 14 concentrations of
the same 3 biomarkers were used to identify additional high-
risk patients from those initially categorized as low risk and
who had not yet developed GVHD. A range of useful speci-
ficities and sensitivities were identified. For example, at 75%
specificity (false positive rate of 25%), 57% of patients who
would later develop GVHD were correctly identified
(Paczesny et al, 2010b). These findings need to be replicated
in multi-centre studies, but data from the following study
suggests that such validation is likely.
Biomarker concentrations were measured following GVHD
onset at days 0, 14 and 28 of GVHD therapy for patients
enrolled on a multi-centre study to predict key GVHD out-
comes, such as day-28 treatment response and day-180 mor-
tality. When combined into a mathematical model assigning
individual weights to each biomarker using logistic regression
modelling, samples at all 3 time points correlated with
clinical response to therapy and mortality (Levine et al,
2012). More importantly, the biomarkers were independent
predictors for GVHD outcomes even after adjusting for clini-
cal predictors, such as severity of GVHD at onset, donor type
and initial response to treatment. These findings suggest that
combining clinical and laboratory risk factors into a single
algorithm will provide more precise GVHD risk assessment
than relying on either alone.
Conclusions
Acute GVHD remains a leading cause of transplant-related
mortality following allo-HCT. Limited progress has been
made in the treatment of GVHD, highlighting the impor-
tance of developing more effective prediction and prevention
strategies. Several clinical, genetic, and biomarker-based risk
factors have been identified that correlate with acute GVHD
risk. Translating these observations into clinical applications
is next. Ultimately, it is possible to envision an algorithm
that predicts risk of GVHD for individual patients based on
established clinical predictors of GVHD (e.g., age, the selec-
tion of an unrelated or alternative donor, HLA-mismatch,
the use of high-dose TBI, etc.), genetic risk factors (e.g. IL10
and NOD2 polymorphisms) and GVHD biomarker concen-
trations measured early enough after HCT (e.g., in the first
days to weeks), so that there is a window of opportunity to
pre-empt clinical GVHD from developing. The first step
will be to identify the most important contributors to
GVHD risk from the long list of potential clinical, genetic,
and proteins involved in the pathophysiology of GVHD
and, for post-HCT biomarkers, to determine the optimal
timing of their measurement. Prospective clinical data and
research sample collection is needed to accomplish this
goal. Next, statistical models will need to be compared to
each other to identify the model(s) that provide the most
useful information with the least cost and complexity. Once
these steps are completed, we will be well positioned to test
GVHD risk stratification schemes that guide risk-adapted
therapy (either through selection of prophylaxis regimen or
the use of pre-emptive therapy) to improve outcomes fol-
lowing allo-HCT.
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